Savaş Gokcek

Dr. Savaş Gokcek

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
MUMehmet Uzun
Mehmet Uzun
SGSavaş Gokcek
Savaş Gokcek
EKErhan Kaya
Erhan Kaya
HSHuseyin Salih Semiz
Huseyin Salih Semiz
Our study aimed to examine the predictive relevance of the Systemic Immune-Inflammation Index (SII) in patients with metastatic castration-resistant prostate cancer (mCRPC). A total of 113 mCRPC patients were assessed. In this descriptive study, SII was calculated using the formula (neutrophil count × platelet count)/lymphocyte count. The optimal threshold for SII, determined via the ROC curve, was 700. Patients with SII ≤ 700 were classified as SII-low, while those with SII > 700 were categorized as SII-high. The median overall survival (mOS) was significantly longer in the low SII group compared to the high SII group (*P = 0.015). In multivariate analysis, Gleason score, albumin levels, CHAARTED volume, and SII were identified as significant prognostic factors. Our findings indicate that SII has a strong correlation with survival and can serve as an independent prognostic marker in mCRPC patients.

15 September 2025 in Medicina
Verified
Journal Article
Open access
PDF file
MUMehmet Uzun
Mehmet Uzun
SGSavaş Gokcek
Savaş Gokcek
MKMelis Kılınç
Melis Kılınç
FEFerhat Ekinci
Ferhat Ekinci
TATUGAY AVCI
TUGAY AVCI
IUIlkay tugba Unek
Ilkay tugba Unek
Background and Objectives: HER-2 expression plays a critical role in the biological behavior and treatment of gastric cancer. With the emergence of HER-2-targeted therapies, classification into negative, low, and positive groups has gained clinical importance. The present study focused on assessing the link between HER-2 status and clinical–pathological variables, metastatic involvement, and overall survival (OS) among advanced gastric cancer patients. Materials and Methods: A total of 300 patients with advanced gastric adenocarcinoma were retrospectively analyzed. The mean age of the 300 patients included in the study was 61.8 years, and 70% of them were male. Based on immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), patients were classified as HER-2-negative (IHC 0), HER-2-low (IHC 1+ or 2+/FISH-negative), or HER-2-positive (IHC 3+ or 2+/FISH-positive). Clinicopathological variables, metastatic sites, and OS were compared among groups using Pearson’s Chi-square, Fisher’s exact test, ANOVA, and Kaplan–Meier survival analysis. Results: Significant differences were observed among HER-2 subgroups in pathological subtype (p = 0.006), liver metastasis (p = 0.009), lung metastasis (p = 0.006), and other metastatic sites (p = 0.001). HER-2-positive patients demonstrated higher rates of adenocarcinoma histology and increased liver and lung metastases. In female patients, HER-2 status was significantly associated with lung (p = 0.001) and other metastases (p < 0.001). Median OS for the entire cohort was 9.83 months (95% CI: 8.29–11.36). HER-2-positive patients had a significantly longer OS (15.06 months) compared with HER-2-negative patients (8.73 months; p = 0.039). Conclusions: HER-2 status is an important predictor of metastatic behavior and survival in advanced gastric cancer. HER-2-positive patients display distinct metastatic patterns and improved outcomes, supporting the value of HER-2-targeted therapies. The HER-2-low group may represent a biologically and clinically relevant intermediate subtype requiring further investigation.

12 March 2026 in Cancers
Verified
Journal Article
Open access
PDF file
BDBENGU DURSUN
BENGU DURSUN
SYSendag Yaslikaya
Sendag Yaslikaya
SSSerhat Sekmek
Serhat Sekmek
TÖTuğba Önder
Tuğba Önder
HYHasan Çağrı Yıldırım
Hasan Çağrı Yıldırım
HAHakan Akbulut
Hakan Akbulut
Background: Achieving no evidence of disease (NED) in HER2-positive metastatic breast cancer (MBC) has been proposed as a response-state marker for durable disease control. However, its clinical significance and predictive factors are not yet well established. Methods: In this multicenter retrospective study at 13 oncology centers in Turkey, we analyzed 118 patients with stage IV HER2-positive MBC who received trastuzumab-based first-line therapy and remained progression-free for at least 36 months. Patients were stratified by radiologically defined NED status according to RECIST v1.1. Clinicopathological features were compared between groups, and predictors of NED were identified using logistic regression. Progression-free survival (PFS) was estimated by Kaplan–Meier analysis and assessed with Cox regression. Results: Of the 118 patients, 55 (46.6%) achieved NED. Compared with patients who did not achieve NED, those attaining NED were younger (median 46 vs. 53 years, p = 0.013), had better ECOG performance status (p = 0.005), were more likely to have HER2 IHC 3+ status (p = 0.015), and higher histologic grade tumors (p = 0.013). In multivariable logistic regression, ECOG PS 0 (vs. 1 ; OR = 5.99, p = 0.005), HER2 IHC 3+ (vs. IHC 2+/ISH+; OR = 4.79, p = 0.035), and histologic grade ≤2 (vs. grade 3 ; OR = 0.25, p = 0.011) were independently associated with NED attainment. Patients who achieved NED had experienced significantly longer PFS than those who did not (median 131 months vs. 66 months; p < 0.005). In multivariate Cox regression, NED remained independently associated with prolonged PFS (HR = 0.24, p = 0.003). Metastasis-directed local therapy and treatment regimen (trastuzumab vs. trastuzumab + pertuzumab) were not independently associated with NED attainment or PFS. Conclusions: In this multicenter cohort of pre-selected long-term responders, nearly half of HER2-positive MBC patients achieved radiologic NED. Radiologic NED was independently associated with prolonged PFS within this enriched population. Factors associated with NED attainment included favorable ECOG performance status, HER2 IHC 3+ expression, and high tumor grade; given the wide confidence intervals, these estimates should be interpreted cautiously as exploratory and hypothesis-generating.

18 November 2022
Verified
Book Chapter
Closed access
SGSavaş Gokcek
Savaş Gokcek
Gestasyonel trofoblastik neoplazi (GTN), mol hidatiform, koryokarsinom, invaziv mol, plasental bölge trofoblastik tümörü (PSTT) ve epiteloid trofoblastik tümör (ETT) gibi plasental trofoblast hücrelerinden köken alan benign ve malign hastalıklar grubunu kapsar. Bu tümörler, normal trofoblast dokusunun endometriuma invazyonunu kontrol eden düzenleyici mekanizmaların bozulması sonucu oldukça invaziv, vasküler ve metastatik bir karakter kazanır. Hastalığın klinik takibi ve tanısı, mol hidatiform boşaltılmasından sonra plato çizen veya yükselen serum hCG seviyelerine dayanır. En sık akciğerler ve alt genital sisteme metastaz yapan GTN’nin prognozu ve tedavi protokolü, FIGO tarafından revize edilen DSÖ prognostik skorlama sistemine göre belirlenir. Düşük riskli (skor ≤6) ve metastatik olmayan olgularda tek ajanlı kemoterapi (metotreksat veya aktinomisin D) ile %100'e yakın tam iyileşme sağlanırken, yüksek riskli (skor >6) veya yaygın metastatik olgularda çok ajanlı agresif kemoterapi rejimleri ve duruma göre cerrahi rezeksiyon uygulanır. Gestational trophoblastic neoplasia (GTN) encompasses a spectrum of benign and malignant disorders originating from placental trophoblastic cells, including hydatidiform mole, choriocarcinoma, invasive mole, placental site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (ETT). These tumors acquire a highly invasive, vascular, and metastatic character because the regulatory mechanisms controlling the endometrial invasion of normal trophoblastic tissue become dysfunctional. Clinical surveillance and diagnosis of the disease rely on serum hCG levels that either plateau or rise following the evacuation of a hydatidiform mole. Most frequently metastasizing to the lungs and lower genital tract, the prognosis and treatment protocols of GTN are determined by the WHO prognostic scoring system revised by FIGO. While low-risk (score ≤6) and non-metastatic cases achieve a cure rate near 100% with single-agent chemotherapy (methotrexate or actinomycin D), high-risk (score >6) or advanced metastatic cases are treated with multi-agent aggressive chemotherapy regimens and tailored surgical resections.

11 March 2026 in IMC Journal of Medical Science
Verified
Journal Article
Open access
SGSavaş Gokcek
Savaş Gokcek
BSBülent Sözmen
Bülent Sözmen
MYMurat Yeşil
Murat Yeşil
Background and Objective: To evaluate the relationship between hemoglobin A1c (HbA1c) levels and angiographic atherosclerotic burden in non-diabetic individuals. Materials and methods: This retrospective study included adult patients who underwent coronary angiography (CAG) at İzmir Atatürk Training and Research Hospital between 2002 and 2006. All clinical, biochemical, and angiographic data were retrieved from archived hospital records. Individuals with a previous diagnosis of diabetes mellitus or with fasting plasma glucose ≥126 mg/dL were excluded. HbA1c levels, routine biochemical parameters, and classical cardiovascular risk factors were evaluated. The extent and severity of coronary artery disease (CAD) were quantified using the Gensini scoring system, which assigns stenosis-based severity points and multiplies them by segment-specific weighting factors to reflect anatomical importance. Patients were classified according to HbA1c categories and number of involved coronary vessels. Correlations between HbA1c, inflammatory markers, and angiographic severity were analyzed. Results: Higher HbA1c levels were associated with increased Gensini scores and greater angiographic atherosclerotic burden. Individuals with HbA1c ≥6.0% showed significantly elevated fibrinogen and C-reactive protein levels, suggesting an accompanying low-grade inflammatory process. Although overall group comparisons indicated a significant difference in HbA1c levels, post-hoc analyses did not reveal differences between specific vessel-involvement subgroups. HbA1c demonstrated a modest but meaningful relationship with subclinical coronary atherosclerosis, independent of lipid parameters. Conclusion: HbA1c may serve as an early, accessible marker of atherosclerotic risk even in individuals without diabetes. This study provides region-specific evidence supporting the integration of HbA1c into cardiovascular risk-stratification strategies for earlier detection and prevention. January 2026; Vol. 20(1):005. DOI: https://doi.org/10.55010/imcjms.20.005 *Correspondence: Savas Gokcek, Department of Medical Oncology, Necip Fazıl City Hospital Kahramanmaraş/Turkey, 46080.Email: gokceksavas35@gmail.com. © 2026 The Author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License(CC BY 4.0).

1 January 2025 in Eurasian Journal of Medical Investigation
Verified
Journal Article
Closed access
PDF file
SGSavaş Gokcek
Savaş Gokcek
EKErhan Kaya
Erhan Kaya
Ejmi Eurasian Journal of Medical Investigation